NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBD

by NImmune Biopharma | May 5, 2026 | Press Release

Download Press Release New data presented at DDW demonstrates that NIM-1324 outperforms current IBD medications, establishes Phase 1 safety, tolerability and LANCL2 target engagement in humans Supports the efficacy of NIM-1324, a de-risked, safe and well-tolerated,...

New Data Presented at IMMUNOLOGY2026 Shows LANCL2 Medicines in Clinical Development for IBD Can Provide Protection from Asthma

by NImmune Biopharma | Apr 20, 2026 | Research and White Papers

NImmune Biopharma, Inc is pleased to share the release of exciting new data on the efficacy of LANCL2 medicines in treating inflammatory diseases and their immunometabolic mechanisms of action at The American Association of Immunologists Annual Meeting,...

NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026

by NImmune Biopharma | Mar 24, 2026 | Press Release

Download Press Release Novel findings to be presented at IMMUNOLOGY2026 demonstrate efficacy of novel LANCL2-targeting therapeutics outperforming current psoriasis treatments in multiple mouse models Newly discovered mechanisms in phagocytes and epithelial cells in...

NImmune Biopharma to Present at DDW’25 the First Ever Head-to-Head Clinical and Translational Results for Omilancor Versus Leading Anti-TL1A in IBD Showing Superiority and Complementarity

by NImmune Biopharma | May 6, 2025 | Press Release

Download Press Release New results affirm omilancor’s ability to safely reverse colonic regulatory T-cell (Treg) depletion and mitochondrial dysfunction in severe UC patients which defines a core subset of patients traditionally refractory to existing approved IBD...

The NIMML Institute and NImmune Biopharma Showcase How the TITAN-X A.I. Platform has Accelerated Therapeutic Development in the Annual Review of Biomedical Data Science

by NImmune Biopharma | Apr 21, 2025 | Press Release

Download Press Release TITAN-X Precision Medicine A.I. Platform identifies therapeutic targets and successfully fueled development of expansible pipelines with leading therapeutic assets in Phase 1-3 clinical testing Integrates A.I., bioinformatics and advanced...